Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wang, Wei ^a   Zhao, Caiyan ^a   Zhou, Junying ^a   Zhen, Zhen ^a   Wang, Yadong ^a   Shen, Chuan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEPROTECH; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT;

ACTINS; ANIMALS; CELLS, CULTURED; COLLAGEN TYPE I; DIET, HIGH-FAT; ENZYME INHIBITORS; FATTY LIVER; GENE EXPRESSION; HEPATIC STELLATE CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; LIVER CIRRHOSIS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84884880038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076538     Document Type: Article

References (37)

1. Younossi ZM, (2008) Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28: 2-12. doi:10.1111/j.1365-2036.2008.03710.x. PubMed: 18410557.
2. Lam BP, Younossi ZM, (2009) Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 8 (Suppl 1):: S51-S59. PubMed: 19381125.
3. Vuppalanchi R, Chalasani N, (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49: 306-317. doi:10.1002/hep.22603. PubMed: 19065650.
4. Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L, et al. (2007) Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550. PubMed: 17729403.
5. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA, (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43: 990-994. doi:10.1097/MCG.0b013e31819c392e. PubMed: 19448566.
6. de Alwis NM, Day CP, (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 (Suppl 1):: S104-S112. doi:10.1016/S0168-8278(08)60259-7. PubMed: 18304679.
7. Dowman JK, Tomlinson JW, Newsome PN, (2010) Pathogenesis of non-alcoholic fatty liver disease. QJM 103: 71-83. doi:10.1093/qjmed/hcp158. PubMed: 19914930.
8. Musso G, Gambino R, Cassader M, (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26. doi:10.1016/j.plipres.2008.08.001. PubMed: 18824034.
9. Asano T, Watanabe K, Kubota N, Gunji T, Omata M, et al. (2009) Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 24: 1669-1676. doi:10.1111/j.1440-1746.2009.06039.x. PubMed: 19788607.
10. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL, (2010) Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 55: 931-940. doi:10.1007/s10620-009-0815-3. PubMed: 19459046.
11. Tarantino G, Savastano S, Colao A, (2010) Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 16: 4773-4783. doi:10.3748/wjg.v16.i38.4773. PubMed: 20939105.
12. Nakano S, Nagasawa T, Ijiro T, Inada Y, Tamura T, et al. (2008) Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res 38: 1026-1039. doi:10.1111/j.1872-034X.2008.00363.x. PubMed: 18513333.
13. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, et al. (2008) Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med 6: 72. doi:10.1186/1479-5876-6-72. PubMed: 19038040.
14. Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, et al. (2012) Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 10: 50. doi:10.1186/1479-5876-10-S2-A50. PubMed: 22424154.
15. Miyaki T, Nojiri S, Shinkai N, Kusakabe A, Matsuura K, et al. (2011) Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res 41: 375-385. doi:10.1111/j.1872-034X.2010.00769.x. PubMed: 21276150.
16. Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, et al. (2012) Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property. Dig Liver Dis 44: 492-496. doi:10.1016/j.dld.2011.12.013. PubMed: 22265683.
17. Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, et al. (2013) Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int 33: 301-311. doi:10.1111/liv.12033. PubMed: 23295058.
18. Abel T, Fehér J, Dinya E, Eldin MG, Kovács A, (2009) Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 15MS6-11: MS6-11. PubMed: 19946244.
19. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, et al. (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47: 135-141. doi:10.1016/j.jhep.2007.02.013. PubMed: 17400325.
20. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, et al. (2003) Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38: 564-572. doi:10.1016/S0270-9139(03)80878-9. PubMed: 12713866.
21. Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, et al. (2008) Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 89: 241-250. doi:10.1111/j.1365-2613.2008.00590.x. PubMed: 18429990.
22. Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, et al. (2009) Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 39: 963-971. doi:10.1111/j.1872-034X.2009.00539.x. PubMed: 19624767.
23. Trocha M, Merwid-Lad A, Szuba A, Chlebda E, Pieśniewska M, et al. (2010) Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep 62: 343-351. doi:10.1124/pr.110.002832. PubMed: 20508290.
24. She H, Xiong S, Hazra S, Tsukamoto H, (2005) Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280: 4959-4967. PubMed: 15537655.
25. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, et al. (2006) PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350: 385-391. doi:10.1016/j.bbrc.2006.09.069. PubMed: 17010940.
26. Lonardo A, Loria P, (2012) If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? Dig Liver Dis 44: 451-452. doi:10.1016/j.dld.2012.02.020. PubMed: 22487461.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. doi:10.1002/hep.20701. PubMed: 15915461.
28. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023. doi:10.1002/hep.25762. PubMed: 22488764.
29. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE, (2009) Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 150: 5262-5272. doi:10.1210/en.2009-0603. PubMed: 19819942.
30. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, et al. (2004) Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126: 749-755. doi:10.1053/j.gastro.2003.12.007. PubMed: 14988829.
31. Dima A, Marinescu AG, Dima AC, (2012) Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 50: 19-25. PubMed: 22788090.
32. Zamin I Jr, Mattos AA, Mattos AZ, Coral G, Santos D, et al. (2010) The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 47: 86-92. doi:10.1590/S0004-28032010000100015. PubMed: 20520981.
33. Tabuchi T, Satoh M, Itoh T, Nakamura M, (2012) MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 123: 161-171. doi:10.1042/CS20110563. PubMed: 22364258.
34. Kok SH, Lin LD, Hou KL, Hong CY, Chang CC, et al. (2013) Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Arthritis Rheum 65: 639-649. doi:10.1002/art.37807. PubMed: 23239110.
35. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, et al. (2013) miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58: 119-125. doi:10.1016/S0168-8278(13)60283-4. PubMed: 22902550.
36. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, et al. (2009) Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651-1658. doi:10.1053/j.gastro.2009.01.043. PubMed: 19208350.
37. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, et al. (2007) Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 46: 1040-1046. doi:10.1016/j.jhep.2007.01.020. PubMed: 17335931.